58 Epigenetic editing as a promising strategy to enhance efficacy and genomic integrity of CAR T cell therapy

Shutan Jiang, Hongye Wang, Shaoshuai Mao, Lei‐Lei Wu, Yaqin Li, Xiaodong Huang, Bob ZhangRegular 2023 · DOI

Abstract

Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematological malignancies. However, the use of site-specific nucleases like CRISPR/Cas9 for gene modification carries risks of chromosomal aberrations. This study introduces EPIREG, a DNA cleavage-free epigenetic modulation technology that achieves high-efficiency, sustainable gene silencing without compromising genomic integrity.

Introduction

While CAR-T therapy has shown transformational impact, enhancing its potency often requires knocking out specific genes to overcome immunosuppressive tumor environments. Traditional methods rely on double-strand DNA breaks, which can lead to unintended structural variations, translocations, and other genomic safety issues. There is a pressing need for "cleavage-free" methods that provide precise control over gene expression while maintaining the structural integrity of the T-cell genome.

Methods: The EPIREG Platform

The researchers developed EPIREG by fusing a DNA cleavage-free domain (such as a deactivated nuclease) with epigenetic modulation effectors. This system "reprograms" the target gene's environment using endogenous regulatory pathways rather than physical cutting. The team utilized computational biology and high-throughput screening to optimize single-guide RNAs (sgRNAs) for precise targeting. These components—EPIREG mRNA and sgRNAs—were delivered into CAR-T cells via electroporation, a standard clinical manufacturing technique.

Results

Delivery and Silencing Efficiency

EPIREG demonstrated exceptional performance in primary human T cells. Electroporation achieved a delivery efficiency of over 96% while maintaining high cell viability. This translated into potent gene silencing, with up to 90% reduction in the expression of target genes A, B, and C.

Flow cytometry and bar graphs showing 96.3% delivery efficiency and sustained silencing of target genes A, B, and C over 15 days.

Durability and Multiplexing

A key advantage of EPIREG is the durability of its effects. Despite the transient nature of mRNA delivery, the epigenetic changes remained stable for more than two weeks—sufficient time for the entire CAR-T manufacturing process. Furthermore, the platform successfully manipulated multiple genes simultaneously without a significant drop in efficiency. These multiplexed modifications resulted in CAR-T cells with improved cytotoxicity and increased cytokine production in both in vitro and in vivo models, all while avoiding the chromosomal risks associated with Cas9.

Conclusion

EPIREG offers a superior strategy for CAR-T cell modification, combining high potency and durability with a significantly improved safety profile. By avoiding the risks associated with Cas9-mediated DNA cleavage, EPIREG paves the way for the next generation of safer, more effective cellular therapies with enhanced genomic integrity.

Summary updated

Abstract

<h3>Background</h3> Chimeric Antigen Receptor T-cell (CAR-T) therapy has shown remarkable effectiveness and transformational impact in treating hematological malignancies and solid tumors. Site-specific nucleases such as TALENs and CRISPR/Cas9 have been applied in CAR-T therapies to enhance its cellular potency and functions. However, Cas9 cleavage might lead to chromosomal aberrations, raising potential safety issues in CAR-T therapy. <h3>Methods</h3> In this study, we developed epigenetic modulation technology (EPIREG) wherein a DNA cleavage-free domain is fused with epigenetic modulation effectors to manipulate disease-causing genes through the endogenous epigenetic regulation pathway. Utilizing computational biology approach in combination with high-throughput screening, we have optimized and selected single-guide RNAs (sgRNAs) for precise, efficient, and sustainable gene modulations. Then the EPIREG mRNA and sgRNAs were delivered into CAR-T cells using electroporation method. <h3>Results</h3> Delivery efficiency into CAR-T cells can reach over 96% (shown in figure 1), while maintaining high cell viability. Consequently, a high level of gene silencing (up to 90% for target gene A, B, and C, respectively, shown in figure 2) was observed. Furthermore, this gene silencing effect was sustained for more than 2 weeks, sufficient manufacturing time for CAR-T cell products. EPIREG also showed capabilities to simultaneously manipulate multiple target genes (efficiency shown in figure 3), thereby strengthening the performance of CAR-T cells. These cells with multiplex gene modifications displayed improved cytotoxicity, increased cytokine production, and sustained presence both <i>in vitro</i> and <i>in vivo</i>. Importantly, EPIREG demonstrated minimal off-target effects and circumvented the risks of chromosomal aberrations associated with Cas9. <h3>Conclusions</h3> EPIREG demonstrated superior potency, durability, and safety for gene modifications in CAR-T cells. Without Cas9-related risks, EPIREG offers a potential and promising strategy in future CAR-T cell therapies with enhanced efficacy and improved genomic integrity.
BibTeX
@inproceedings{jiang2023epigenetic,
  author = {Shutan Jiang and Hongye Wang and Shaoshuai Mao and Lei‐Lei Wu and Yaqin Li and Xiaodong Huang and Bob Zhang},
  title = {{58 Epigenetic editing as a promising strategy to enhance efficacy and genomic integrity of CAR T cell therapy}},
  booktitle = {Regular},
  year = {2023},
  doi = {10.1136/jitc-2023-sitc2023.0058},
}
Figure